Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01666314
• Other study ID #: C21013
• Secondary ID: 2012-001539-30U1
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: August 6, 2012
• Last updated: February 19, 2018
• Start date: August 20, 2012
• Est. completion date: September 1, 2016

Study information

• Verified date: February 2018
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled, multiregional Phase1/2 study to characterize the pharmacokinetic and pharmacodynamic responses to orteronel when administered concomitantly with prednisone in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Description:

The drug being tested in this study is called orteronel. Orteronel is being tested to treat adult males who have adenocarcinoma of the prostate. This study will look at the pharmacokinetics (how the drug moves through the body) and pharmacodynamics (how the drug effects the body) in people who take orteronel in addition to prednisone.

The study will enroll approximately 144 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the eight treatment groups (4 in Japan, 4 in Ex-Japan) which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need).

In Japan:

Participants were randomized in a ratio of 2:1:2:1

• 200 mg orteronel or Placebo-matching orteronel [(dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient] twice daily (BID) + prednisone

• 300 mg orteronel, or Placebo-matching orteronel, BID + prednisone Ex-Japan Participants were randomized in a ratio of 2:1:2:1

• 200 mg orteronel or Placebo-matching orteronel, BID in Cycle 1 + prednisone

• 400 mg orteronel, or Placebo-matching orteronel ,BID in Cycle 1 + Prednisone

Participants initially randomized to placebo received 4 weeks of placebo and then 12 weeks of active treatment with orteronel then entered a follow-up period treatment period. Participants initially randomized to orteronel received 16 weeks of treatment then entered a follow-up treatment period.

This multi-centre trial will be conducted worldwide. The overall time to participate in this study is approximately 3.2 years. Participants will make multiple visits to the clinic and a final visit 30 to 40 days after receiving their last dose of study drug for a follow-up assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 137
• Est. completion date: September 1, 2016
• Est. primary completion date: September 12, 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male participants 18 years or older

• Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care

• Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma

• Prior surgical castration or concurrent use of an agent for medical castration [e.g. Gonadotropin-releasing hormone (GnRH) analogue]

• Prostate-Specific Antigen (PSA) = 2 ng/mL at screening

• Progressive disease based on PSA and/or radiographic criteria

Exclusion Criteria:

• Prior therapy with orteronel, ketoconazole, aminoglutethimide, or abiraterone.

• Known hypersensitivity to compounds related to orteronel, orteronel excipients, prednisone (or commercially available equivalent), or GnRH analogue.

• All antiandrogen therapy (including bicalutamide) is excluded within 4 weeks before the first dose of study drug. Any other therapies for prostate cancer, other than GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5- alpha reductase inhibitors (e.g., finasteride or dutasteride), must be discontinued 2 weeks before the first dose of study drug.

• Continuous daily use of oral prednisone (or commercially available equivalent), oral dexamethasone, or other systemic corticosteroids for more than 2 weeks within the 3 months before screening (inhaled, nasal, and local steroids [e.g., joint injection] are allowed).

• Prior chemotherapy for prostate cancer, with the exception of neoadjuvant/adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years before screening.

Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Orteronel
Orteronel tablets
• Orteronel Placebo
Orteronel placebo-matching tablets
• Prednisone
Prednisone 5 mg

Locations

Country	Name	City	State
United States	Urology Cancer Center, PC	Omaha	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Serum Testosterone Levels Reduced to = 2 ng/dL After 4 Weeks of Treatment in Japan	Serum Ultra-sensitive testosterone was measured by liquid chromatography at a central laboratory.	Baseline and Week 4
Secondary	Percentage of Participants With Serum Testosterone Levels Reduced to = 2 ng/dL in Ex-Japan	Serum Ultra-sensitive testosterone was measured by liquid chromatography at a central laboratory.	Baseline and Week 4
Secondary	Percent Change From Baseline in Serum Testosterone Level After 4 Weeks of Treatment	Serum Ultra-sensitive testosterone was measured by liquid chromatography at a central laboratory.	Baseline and Week 4
Secondary	Percent Change From Baseline in Serum Testosterone Level After 12 Weeks of Treatment	Serum Ultra-sensitive testosterone was measured by liquid chromatography at a central laboratory.	Baseline and Week 12
Secondary	Percentage of Participants With Prostate-Specific Antigen Reduction = 50% (PSA50) After 4 Weeks of Treatment	A 50% PSA response rate (PSA50) was defined as PSA reduction = 50% from Baseline.	Baseline and Week 4
Secondary	Percentage of Participants With PSA50 After 12 Weeks of Treatment	A 50% PSA response rate (PSA50) was defined as PSA reduction = 50% from Baseline.	Baseline and Week 12
Secondary	Absolute Values for Testosterone	Serum Ultra-sensitive testosterone was measured by liquid chromatography at a central laboratory.	Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Secondary	Absolute Values for Dehydroepiandrosterone Sulfate (DHEA-S)	Serum Ultra low level quantification of DHEA-S was measured by liquid chromatography and mass spectrometry (LC/MS) at a central laboratory.	Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Secondary	Absolute Values for Adrenocorticotropic Hormone (ACTH)	Serum ACTH was measured by immunometric assay at the central laboratory.	Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Secondary	Absolute Values for Corticosterone	Serum Corticosterone was measured by high pressure liquid chromatography with mass spectrometry at the central laboratory.	Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Secondary	Absolute Values for Cortisol	Serum Cortisol was measured by immunometric assay at the central laboratory.	Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Secondary	Absolute Values for Prostate-Specific Antigen (PSA)	Serum PSA was measured at the central laboratory.	Baseline and Cycle 2 Day 1
Secondary	Cmax: Maximum Observed Plasma Concentration for Orteronel and M-I Metabolite	Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.	Cycle 1 Day 1 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	AUC(0-12): Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hours Post-dose for Orteronel and M-I Metabolite	AUC(0-12) is measure of area under the curve over the dosing interval where the length of the dosing interval is time 0 to 12 hours in this study.	Cycle 1 Day 1 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Orteronel and M-I Metabolite	Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.	Cycle 1 Day 1 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	AE (0-24) Cumulative Amount of Drug Excreted Into the Urine for Orteronel and MI-Metabolite	Cumulative amount of urine excreted time 0 to 24 hour.	Cycle 1 Day 1 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	Cmax,ss: Maximum Observed Plasma Concentration at Steady State for Orteronel and MI-Metabolite	Maximum observed steady-state plasma concentration during a dosing interval.	Cycle 1 Day 8 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	Tmax,ss: Time to Reach the Maximum Plasma Concentration (Cmax), Equal to Time (Hours) to Cmax at Steady State for Orteronel and M-I Metabolite	Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax at steady state.	Cycle 1 Day 8 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Orteronel and M-I Metabolite	Area under the plasma concentration-time curve during a dosing interval, where tau is the length of the dosing interval.	Cycle 1 Day 8 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	Rac: Accumulation Index for Orteronel and M-I Metabolite	Rac was calculated as the ratio of AUCtau to AUC12hr.	Cycle 1 Day 8 Predose, 0.5, 1, 2, 3, 5, 8, 12 hours post-dose
Secondary	Ctrough,ss: Observed Predose Plasma Concentration at Steady State for Orteronel and M-I Metabolite	Observed predose plasma concentration at steady state.	Cycle 1 Day 8 Predose
Secondary	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding),symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.	From signing of the informed consent form through 30 days after the last dose of study drug, approximately 3.2 years